Nat Methods:高端成像技术让癌细胞无所遁形

2015-11-12 佚名 生物谷

图片来源:medicalxpress.com 利用高科技的成像方法,来自华盛顿大学的科学家就可以在组织深处清楚地看到早期发育中的癌细胞,这或许比之前利用荧光蛋白来观察癌细胞要更加清晰直观,相关研究发表于国际杂志Nature Methods上。 研究者Lihong Wang表示,通过遗传性地修饰胶质母细胞瘤细胞使其表达BphP1蛋白,我们就可以利用光声层析成像 (Photoacoustic

图片来源:medicalxpress.com

利用高科技的成像方法,来自华盛顿大学的科学家就可以在组织深处清楚地看到早期发育中的癌细胞,这或许比之前利用荧光蛋白来观察癌细胞要更加清晰直观,相关研究发表于国际杂志Nature Methods上。

研究者Lihong Wang表示,通过遗传性地修饰胶质母细胞瘤细胞使其表达BphP1蛋白,我们就可以利用光声层析成像 (Photoacoustic tomography)在组织1厘米深处清楚地观测成百上千个活的癌细胞,光声层析成像技术是一种新型的无损无创生物医学影象技术;本文研究工作中研究人员首次将深度侵入技术、高分辨率的光声成像技术同可逆转的可变开关非荧光的细菌光敏色素相结合进行研究。

研究者指出,蛋白质的遗传编码可以使得我们对组织深处的生物学过程进行成像并且靶向追踪,而蛋白质的光控开关特性也可用作新的成像功能;BphP1蛋白可以感知不用类型的光,同时相应改变其吸收特性,这种特性就可以帮助研究者利用两种类型的光:红光或近红外光来获取癌性组织的成像结果,同时也可以对成像结果进行对比来获取癌细胞高度敏感性及高分辨率的成像结果。

利用光声层析成像技术,研究人员首先在近红外光的帮助下揭示了癌性组织中所表达的特殊蛋白,使其改变了吸收特性,随后研究者利用红光照射癌性组织,即扳动蛋白开关以便其可以回归至原始状态。当减去二次成像后血液信号和其它未知的成像背景就会被消除,以便研究者可以更加清晰地观察癌细胞的存在及其转移过程。

研究者Yao指出,本文研究中所开发的新技术对于癌症成像非常有用,当我们首次观看到早期癌症发生时,癌症组织和健康组织并无差异,因为丰富的血液会给予其足够强的信号,使得癌细胞不会凸显出来,如今利用这种新技术研究者就可以在癌症规模很小的时候就对其进行观察研究。

此前研究中仅可以在组织中观看到相对晚期的癌症细胞,因为来自血液较强的背景信号会遮挡癌细胞,而本文中研究人员所开发的新技术不仅可以帮助进行癌症研究,同时还可以用于心脏组织和癌症免疫疗法的研究,新型技术的开发为生物学家们提供了一种新型的工具来进行癌症遗传特异性的高分辨率及深度成像研究,同时也将助力癌症新型药物的研发。

原文出处:

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1880863, encodeId=db29188086308, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Thu May 05 17:06:00 CST 2016, time=2016-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895848, encodeId=b9c218958486e, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Mon Jan 04 20:06:00 CST 2016, time=2016-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=43317, encodeId=5ddf4331e9d, content=新技术, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=21de1652194, createdName=1ddcd6e4m96(暂无匿称), createdTime=Tue Nov 17 15:31:00 CST 2015, time=2015-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252059, encodeId=b6151252059df, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Sat Nov 14 02:06:00 CST 2015, time=2015-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1570734, encodeId=c49115e0734ee, content=<a href='/topic/show?id=03d55395183' target=_blank style='color:#2F92EE;'>#成像技术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53951, encryptionId=03d55395183, topicName=成像技术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d6b515702368, createdName=photoman, createdTime=Sat Nov 14 02:06:00 CST 2015, time=2015-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=43086, encodeId=dc9e43086ec, content=新技术, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4bfa83595, createdName=jetleo, createdTime=Fri Nov 13 01:13:00 CST 2015, time=2015-11-13, status=1, ipAttribution=)]
    2016-05-05 liye789132251
  2. [GetPortalCommentsPageByObjectIdResponse(id=1880863, encodeId=db29188086308, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Thu May 05 17:06:00 CST 2016, time=2016-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895848, encodeId=b9c218958486e, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Mon Jan 04 20:06:00 CST 2016, time=2016-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=43317, encodeId=5ddf4331e9d, content=新技术, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=21de1652194, createdName=1ddcd6e4m96(暂无匿称), createdTime=Tue Nov 17 15:31:00 CST 2015, time=2015-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252059, encodeId=b6151252059df, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Sat Nov 14 02:06:00 CST 2015, time=2015-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1570734, encodeId=c49115e0734ee, content=<a href='/topic/show?id=03d55395183' target=_blank style='color:#2F92EE;'>#成像技术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53951, encryptionId=03d55395183, topicName=成像技术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d6b515702368, createdName=photoman, createdTime=Sat Nov 14 02:06:00 CST 2015, time=2015-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=43086, encodeId=dc9e43086ec, content=新技术, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4bfa83595, createdName=jetleo, createdTime=Fri Nov 13 01:13:00 CST 2015, time=2015-11-13, status=1, ipAttribution=)]
    2016-01-04 一闲
  3. [GetPortalCommentsPageByObjectIdResponse(id=1880863, encodeId=db29188086308, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Thu May 05 17:06:00 CST 2016, time=2016-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895848, encodeId=b9c218958486e, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Mon Jan 04 20:06:00 CST 2016, time=2016-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=43317, encodeId=5ddf4331e9d, content=新技术, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=21de1652194, createdName=1ddcd6e4m96(暂无匿称), createdTime=Tue Nov 17 15:31:00 CST 2015, time=2015-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252059, encodeId=b6151252059df, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Sat Nov 14 02:06:00 CST 2015, time=2015-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1570734, encodeId=c49115e0734ee, content=<a href='/topic/show?id=03d55395183' target=_blank style='color:#2F92EE;'>#成像技术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53951, encryptionId=03d55395183, topicName=成像技术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d6b515702368, createdName=photoman, createdTime=Sat Nov 14 02:06:00 CST 2015, time=2015-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=43086, encodeId=dc9e43086ec, content=新技术, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4bfa83595, createdName=jetleo, createdTime=Fri Nov 13 01:13:00 CST 2015, time=2015-11-13, status=1, ipAttribution=)]
    2015-11-17 1ddcd6e4m96(暂无匿称)

    新技术

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1880863, encodeId=db29188086308, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Thu May 05 17:06:00 CST 2016, time=2016-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895848, encodeId=b9c218958486e, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Mon Jan 04 20:06:00 CST 2016, time=2016-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=43317, encodeId=5ddf4331e9d, content=新技术, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=21de1652194, createdName=1ddcd6e4m96(暂无匿称), createdTime=Tue Nov 17 15:31:00 CST 2015, time=2015-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252059, encodeId=b6151252059df, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Sat Nov 14 02:06:00 CST 2015, time=2015-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1570734, encodeId=c49115e0734ee, content=<a href='/topic/show?id=03d55395183' target=_blank style='color:#2F92EE;'>#成像技术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53951, encryptionId=03d55395183, topicName=成像技术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d6b515702368, createdName=photoman, createdTime=Sat Nov 14 02:06:00 CST 2015, time=2015-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=43086, encodeId=dc9e43086ec, content=新技术, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4bfa83595, createdName=jetleo, createdTime=Fri Nov 13 01:13:00 CST 2015, time=2015-11-13, status=1, ipAttribution=)]
    2015-11-14 yxch36
  5. [GetPortalCommentsPageByObjectIdResponse(id=1880863, encodeId=db29188086308, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Thu May 05 17:06:00 CST 2016, time=2016-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895848, encodeId=b9c218958486e, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Mon Jan 04 20:06:00 CST 2016, time=2016-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=43317, encodeId=5ddf4331e9d, content=新技术, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=21de1652194, createdName=1ddcd6e4m96(暂无匿称), createdTime=Tue Nov 17 15:31:00 CST 2015, time=2015-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252059, encodeId=b6151252059df, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Sat Nov 14 02:06:00 CST 2015, time=2015-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1570734, encodeId=c49115e0734ee, content=<a href='/topic/show?id=03d55395183' target=_blank style='color:#2F92EE;'>#成像技术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53951, encryptionId=03d55395183, topicName=成像技术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d6b515702368, createdName=photoman, createdTime=Sat Nov 14 02:06:00 CST 2015, time=2015-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=43086, encodeId=dc9e43086ec, content=新技术, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4bfa83595, createdName=jetleo, createdTime=Fri Nov 13 01:13:00 CST 2015, time=2015-11-13, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1880863, encodeId=db29188086308, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Thu May 05 17:06:00 CST 2016, time=2016-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895848, encodeId=b9c218958486e, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Mon Jan 04 20:06:00 CST 2016, time=2016-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=43317, encodeId=5ddf4331e9d, content=新技术, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=21de1652194, createdName=1ddcd6e4m96(暂无匿称), createdTime=Tue Nov 17 15:31:00 CST 2015, time=2015-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252059, encodeId=b6151252059df, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Sat Nov 14 02:06:00 CST 2015, time=2015-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1570734, encodeId=c49115e0734ee, content=<a href='/topic/show?id=03d55395183' target=_blank style='color:#2F92EE;'>#成像技术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53951, encryptionId=03d55395183, topicName=成像技术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d6b515702368, createdName=photoman, createdTime=Sat Nov 14 02:06:00 CST 2015, time=2015-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=43086, encodeId=dc9e43086ec, content=新技术, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4bfa83595, createdName=jetleo, createdTime=Fri Nov 13 01:13:00 CST 2015, time=2015-11-13, status=1, ipAttribution=)]
    2015-11-13 jetleo

    新技术

    0

相关资讯

Science:成像技术活体监测HIV的扩散过程

逆转录病毒(比如HIV)如何在宿主中进行扩散,目前科学家们并不清楚,近日,来自耶鲁大学的研究人员通过研究设计了一种方法,可以在活的有机体中实现对HIV扩散过程的观察,相关研究刊登在了国际杂志Science上,文章中研究者成功观察到了HIV如何到达并且在小鼠淋巴结中实现扩散的过程。研究者Walther Mothes教授说道,我们所观察到的病毒的扩散方式和人们想象中并不相同,实验中我们对小鼠机体中荧光

PLoS ONE:促进生物成像技术发展的新型红外线蛋白标记物

近些年来开发的新型荧光蛋白Amrose已经被广泛地应用于先进的近红外线成像过程中,近日,利用新型的进化平台技术,来自德国环境健康研究中心的研究人员开发了一种新型的红外线标记物,其可以有效帮助改善对组织的成像情况,相关研究成果刊登于国际杂志PLoS ONE上。 远红外转移荧光组织标记物可以使得先进的生物成像技术对组织结构进行清楚成像,从而就可以对肿瘤和癌症转移进行追踪成像,并且对药物的反应进行

Nat Rev Cancer:成像技术带来的革命

治愈癌症是许多科学家奋斗一生的目标。现在人们已经开发了一些抗癌药物,癌症的生存率也逐渐提高,但是这些药物并不完美。英国爱丁堡大学的科学家们认为,活细胞和组织成像技术的进步,将为癌症药物的研发领域带来一场革命。 《自然癌症综述》(Nature reviews caner)是 Nature 旗下介绍癌症研究最新进展的权威期刊,是世界公认的肿瘤研究领域的顶尖综述杂志。日前该期刊上发表了一篇综述,介

Cancer Res:新型成像技术助力癌症研究治疗

刊登在过国际杂志Cancer Research上的一篇研究论文中,来自达特茅斯Geisel医学院的研究人员开发了一种新型的荧光成像技术,其可以不在活组织检查的情况下精确鉴别出靶向癌症疗法的特殊受体。研究者Kimberley S. Samkoe教授说道,蛋白质的过度表达往往是特殊癌症的一个标志,而且也常常在临床肿瘤学领域通过检测肿瘤来用于开发癌症患者的个体化疗法;蛋白质的表达可以通过对肿瘤组织的总蛋

全息成像技术让你360°观察未出生胎儿

飞利浦公司和以色列真实视野图像处理公司联手研制一个全息图像系统,近期,他们在心脏病手术中进行首次系统测试。他们对8名患者进行测试,并且与以色列施耐德儿童医疗中心进行合作。 基于飞利浦介入性X射线和心脏超声技术,该系统用于呈现交互式、实时3D全息图像。除了在2D显示屏上观看患者心脏之外,研究小组的医生还能够在微创心脏手术中观看患者心脏“漂浮在空中”所呈现的3D全息图像,期间无需使用特殊的眼镜。